Crossmark

Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy

Crossref DOI link: https://doi.org/10.1007/s12672-025-02601-4

Published Online: 2025-05-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chao, Ta-Chung

Gracia, Deanna

Ho, Chan-Heng

Chen, Hao-Yang

Huang, Chi-Cheng

Tseng, Ling-Ming
Funding

Funding for this research was provided by:

Taipei Veterans General Hospital (V114C-030)
License Information

Text and Data Mining valid from 2025-05-16

Version of Record valid from 2025-05-16
More Information

Article History

Received: 27 February 2025

Accepted: 6 May 2025

First Online: 16 May 2025

Declarations

:

: The entire study protocol has been reviewed and approved by the Institute Review Board of Taipei Veterans General Hospital. Informed consent was waived as only anonymized cancer registry data were used.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below